On Sept. 14, 2020, Mateon Therapeutics announced that its global study based on its ARTI-19 protocol for Artemisinin Intervention against COVID-19 had been cleared for patient enrollment in India.

The development of Artemisinin against COVID-19, dependent on the successful completion of the ARTI-19 clinical trial ‘Artemisinin Intervention trial against COVID-19’, was initiated globally in Africa, India, and South America.